Beacon Therapeutics Shares 36-Month Interim Data from HORIZON Phase I/2 Trial of AGTC-501 for XLRP Patients.

RYBREVANT® (amivantamab-vmjw) with standard care now approved in the U.S. as the sole targeted treatment reducing disease progression risk by over 50% for second-line EGFR-mutated advanced lung cancer.

Edgewise Therapeutics Reports Favorable Results from Phase 1 Study in Healthy Volunteers and Phase 2 CIRRUS-HCM Study in Obstructive Hypertrophic Cardiomyopathy Patients.

4DMT Showcases Strong and Lasting Clinical Outcomes for 4D-150 and Unveils 4FRONT Phase 3 Program Plan at 4D-150 Wet AMD Development Event.

Transcenta Shares Promising Results from First-Line Triple Combination Trial of Osemitamab (TST001) for G/GEJ Cancer at ESMO 2024.

Genentech revealed favorable topline results from the Phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil).

Satellos Bioscience announced that the initial participant has received a dose in a Phase 1 clinical trial of SAT-3247.

Fasenra granted approval in the United States for treatment of eosinophilic granulomatosis with polyangiitis.

Givastomig is a pioneering first-in-class bispecific antibody immunostimulant targeting Claudin18.2 (CLDN18.2) and 4-1BB.

The FDA has greenlighted Novartis' Kisqali® to lower the chance of recurrence in patients with early-stage HR+/HER2- breast cancer.

Innovent Presents Clinical Results of IBI363 (Novel PD-1/IL-2α-bispecific Antibody) with Bevacizumab in Advanced Colorectal Cancer at 2024 ESMO Congress.

Senhwa Biosciences submits IND to FDA for NCI-sponsored Pidnarulex pharmacodynamics pilot study in advanced solid tumor patients.